Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Holdings Lifted by HighVista Strategies LLC

HighVista Strategies LLC increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 140.2% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,010 shares of the company's stock after purchasing an additional 12,848 shares during the period. HighVista Strategies LLC's holdings in Vera Therapeutics were worth $973,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock worth $86,000 after acquiring an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Vera Therapeutics during the second quarter valued at $135,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vera Therapeutics during the second quarter worth $163,000. Cetera Advisors LLC acquired a new position in shares of Vera Therapeutics in the 1st quarter valued at about $235,000. Finally, Quarry LP bought a new stake in shares of Vera Therapeutics during the 2nd quarter valued at about $235,000. 99.21% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Beth C. Seidenberg sold 15,000 shares of Vera Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the transaction, the director now owns 131,553 shares of the company's stock, valued at approximately $6,318,490.59. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the company's stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50. Following the sale, the chief executive officer now directly owns 307,972 shares of the company's stock, valued at $11,548,950. This represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 89,927 shares of company stock worth $3,800,796. 21.70% of the stock is owned by insiders.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock traded down $0.17 during trading on Tuesday, hitting $49.38. The stock had a trading volume of 345,445 shares, compared to its average volume of 893,052. The business has a fifty day moving average of $44.31 and a two-hundred day moving average of $39.80. Vera Therapeutics, Inc. has a fifty-two week low of $13.09 and a fifty-two week high of $51.61. The firm has a market cap of $3.13 billion, a P/E ratio of -18.92 and a beta of 1.08. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.21). On average, sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wedbush lifted their target price on Vera Therapeutics from $30.00 to $38.00 and gave the company a "neutral" rating in a research note on Friday, November 8th. Scotiabank began coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $60.00 price objective for the company. Evercore ISI upgraded Vera Therapeutics to a "strong-buy" rating in a research note on Monday, September 16th. Guggenheim increased their price objective on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Finally, Wells Fargo & Company started coverage on Vera Therapeutics in a research note on Thursday, November 21st. They set an "overweight" rating and a $70.00 target price on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Vera Therapeutics presently has a consensus rating of "Buy" and an average price target of $59.22.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.